GlaxoSmithKline UK

Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com

Summary of Product Characteristics last updated on the eMC: 21/08/2009
SPC Warticon Solution


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Warticon


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Podophyllotoxin 5 mg/ml (0.5% w/v). The quality of podophyllotoxin fulfills in-house specification.


Go to top of the page
3. PHARMACEUTICAL FORM

Topical solution


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For the topical treatment of condylomata acuminata affecting the penis and the external female genitalia.


Go to top of the page
4.2 Posology and method of administration

The affected area should be thoroughly washed with soap and water, and dried prior to application.

Warticon is applied twice daily for 3 days. If residual warts persist, this 3-day treatment may be repeated weekly, if necessary, for a total of 4 weeks of treatment.

Where lesions are greater than 4 cm2, it is recommended that treatment takes place under the direct supervision of medical staff.


Go to top of the page
4.3 Contraindications

Open wounds following surgical procedures should not be treated with podophyllotoxin.

Hypersensitivity to podophyllotoxin is a contra-indication.

Use in children.

Concomitant use with other podophyllotoxin containing preparations.

Pregnancy and lactation.


Go to top of the page
4.4 Special warnings and precautions for use

Avoid contact with eyes. Should the solution accidentally come into contact with the eye, the eye should be thoroughly rinsed with water.

The hands should be thoroughly washed after each application. Prolonged contact with healthy skin must be avoided since the solution contains an active pharmaceutical substance which could be harmful on healthy skin.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None presently known.


Go to top of the page
4.6 Pregnancy and lactation

The product is not for use in pregnancy or lactation.

Reproduction toxicity studies in animals have not given evidence of an increased incidence of foetal damage or other deleterious effects on the reproductive process. However, since podophyllotoxin is a mitosis inhibitor, Warticon Solution should not be used during pregnancy or lactation.

It is not known if the substance is excreted into breast milk.

Observations in man indicate that podophyllin, a crude mixture of lignans, can be harmful to pregnancy. Such observations have not been reported in patients treated with podophyllotoxin.


Go to top of the page
4.7 Effects on ability to drive and use machines

None presently known.


Go to top of the page
4.8 Undesirable effects

Local irritation may occur on the second or third day of application associated with the start of wart necrosis. In most cases the reactions are mild. Tenderness, itching, smarting, erythema, superficial epithelial ulceration and balanoposthitis have been reported. Local irritation decreases after treatment.


Go to top of the page
4.9 Overdose

There have been no reported overdosages with Warticon Solution. However, excessive use of podophyllotoxin 0.5% solution has been reported as causing two cases of severe local reactions. In cases of excessive use of Warticon Solution resulting in severe local reaction, the treatment should be stopped, the area washed and symptomatic treatment introduced. No specific antidote is known. In the event of accidental ingestion, give emetic or stomach washout. Treatment should be symptomatic and in severe oral overdose ensure the airway is clear and give fluids. Check and correct electrolyte balance, monitor blood gases and liver function. Blood count should be monitored for at least 5 days.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Pharmaco-therapeutic group: D06B B Antivirals

Podophyllotoxin is a metaphase inhibitor in dividing cells binding to at least one binding site on tubulin. Binding prevents tubulin polymerisation required for microtubule assembly. At higher concentrations podophyllotoxin also inhibits nucleoside transport through the cell membrane.

The chemotherapeutic action of podophyllotoxin is assumed to be due to inhibition of growth and the ability to invade the tissue of the viral infected cells.


Go to top of the page
5.2 Pharmacokinetic properties

Topical Administration of a 0.5% solution of ethanolic podophyllotoxin in the majority of cases only requires volumes in the range of 0.1 ml to 0.2 ml. Studies monitoring serum drug level reveal that topical application of a twice daily dose of 100MCL to the penile preputial cavity in 10 patients resulted in a maximum serum concentration of 0.25 ng/ml.


Go to top of the page
5.3 Preclinical safety data

No relevant findings


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Phosphoric acid Ph Eur

Ethanol BP

Purified Water Ph Eur

Patent Blue V (E131)


Go to top of the page
6.2 Incompatibilities

None known.


Go to top of the page
6.3 Shelf life

36 months


Go to top of the page
6.4 Special precautions for storage

Should be stored below 25oC.


Go to top of the page
6.5 Nature and contents of container

An amber glass bottle with plastic child-proof cap. Each bottle contains 3 ml of Warticon Solution. The outer carton also includes a tube containing plastic applicators. Each loop will carry approximately 5μl Warticon Solution.


Go to top of the page
6.6 Special precautions for disposal and other handling

The solution is applied by the plastic applicators provided.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Stiefel Laboratories (UK) Ltd

Eurasia Headquarters

Concorde Road

Maidenhead

SL6 4BY

UK


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL0174/0211


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

21st June 1999 / 8th October 2003


Go to top of the page
10. DATE OF REVISION OF THE TEXT

August 2009



More information about this product

Link to this document from your website: http://emc.medicines.org.uk/medicine/7316/SPC/Warticon Solution/


Active Ingredients/Generics

 
   podophyllotoxin


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk